Sign in
Taking peoplePhase 4

Dapagliflozin for adults with repaired tetralogy of Fallot and leaky pulmonary valve

Tests dapagliflozin on heart and lung function in adults with repaired tetralogy of Fallot.

Key facts

Who runs it
The University of Hong Kong
Where
Hong Kong1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial
Status
Recruiting
Phase
Phase 4
People taking part
106 people, planned
Started
12 May 2025
Expected to end
31 Dec 2026
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • SGLT2 inhibitor (Dapagliflozin 10mg)
Record updated
28 October 2026

Who can take part

The trial is looking for adults who had surgery to repair tetralogy of Fallot, a heart defect present from birth. It tests whether dapagliflozin improves heart and lung function.

Age
18 years or above
Sex
All sexes can join.
Disease stage
Repaired tetralogy of Fallot (rTOF).
Earlier treatment
People cannot join if they used an SGLT2 inhibitor in the last 6 months.
Main reasons for not taking part
  • Heart failure with LVEF < 40%
  • Heart or other surgery planned in the next 3 months
  • Chronic kidney disease stages 4 to 5
  • Diabetes needing insulin, past diabetic ketoacidosis, or low blood sugar with symptoms in the last 6 months
  • Pregnancy or breast feeding
Show the full registry criteria (17)Hide the full registry criteria

Who can take part

  • rTOF
  • Aged 18 years or above
  • Voluntarily agrees to participate in the clinical trial and provide written informed consent

Who cannot take part

  • Recent use of SGLT2 inhibitors within 6 months
  • Other known contraindication to SGLT2 inhibitor
  • Planned cardiac and/or non-cardiac surgery in 3 months
  • Chronic kidney disease stages 4 to 5
  • Known hypersensitivity to SGLT2 inhibitors
  • History of diabetic ketoacidosis
  • Insulin dependent diabetes mellitus
  • History of perineum infection
  • Recent urinary tract infection within 6 months
  • Recent genital infection within 6 months
  • Heart failure with reduced ejection fraction (HFrEF) with LVEF < 40%
  • Unable to perform cardiopulmonary test
  • Recent symptomatic hypoglycaemia within 6 months
  • Pregnancy or breast feeding

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age

This trial is currently available in Hong Kong.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Repaired Tetralogy of Fallot (rTOF) is the leading cause of congenital cyanotic heart disease worldwide, involving up to 7-10% of congenital heart disease. With advances in open-heart surgical repair techniques and medical therapies, there is a significant increase in patients with rTOF surviving till late adulthood. One sequalae that nearly all rTOF patients develop during their lifetime is significant pulmonary regurgitation. Pulmonary regurgitation causes progressive right ventricular dilatation and systolic dysfunction, which in turn impairs cardio-pulmonary function and overall survival.

Read full original descriptionShow less

There is currently no pharmacological therapy proven to improve cardio-pulmonary function in rTOF patients. In a double-blind, placebo controlled, randomized controlled trial involving 33 rTOF patients, the use of beta-adrenergic receptor blocker Bisoprolol failed to improve maximal oxygen uptake (VO2 max) in the treatment group. Furthermore, there was no significant change in dimension of right ventricle on cardiac imaging, or heart failure biomarkers including brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP). In the APPROPRIATE trial involving 64 patients, angiotensin-converting-enzyme inhibitor (ACEI) Ramipril similarly failed to improve VO2 max despite an improved right ventricular long-axis shortening. In REDEFINE trial, 95 rTOF patients were randomized in to receive angiotensin receptor blocker (ARB) Losartan and control. At the end of study, there was no significant difference between the two groups in VO2 max, right ventricular ejection fraction, and other key outcomes.

Sodium-glucose cotransporter 2 (SGLT2) inhibitor is a promising therapy for rTOF patients. Clinical trials consistently demonstrated that SGLT2 inhibitors reduce heart failure hospitalization and mortality among patients with heart failure with or without diabetes mellitus. There have been growing body of evidence that demonstrate that SGLT2 inhibitors improve right ventricular function. In a preclinical study of rat with pulmonary hypertension induced right ventricular failure, empagliflozin was found to reduce pulmonary pressure, alleviate right ventricular hypertrophy and reduce myocardial fibrosis. In a pilot study involving 10 patients with adult congenital heart disease and systemic right ventricular failure, SGLT2 inhibitors improved cardio-pulmonary function as reflected by 6-minute walk test performance and New York Heart Association functional status. Most recently, investigators from DAPA-SERVE randomized controlled trial reported that among 92 patients with systemic right ventricular failure, those randomized to receive SGLT2 inhibitors had superior systemic right ventricular function with larger fractional area change (FAC) and more negative free-wall global longitudinal strain. Nevertheless, as these trials involve patients with right ventricular connections to the systemic circulation rather than pulmonary circulation in rTOF, it is uncertain whether the trial results can be extrapolated to the rTOF population. The critical knowledge gap our proposed randomized controlled trial seeks to address is whether SGLT2 inhibitors improve cardio-pulmonary function in rTOF patients.

The 2 groups in the trial

  • SGLT2 inhibitor GroupTreatment being tested

    Dapagliflozin 10mg once daily orally from Visit 1 (Week 1) to Visit 3 (Week 12 ± 1)

    Treatment: SGLT2 inhibitor (Dapagliflozin 10mg)

  • Control GroupNo study treatment, for comparison

    Routine care

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial (STEPS Trial)
Plain-language title
Dapagliflozin for adults with repaired tetralogy of Fallot and leaky pulmonary valveGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT06668389, who can take part
Record updated
28 October 2026